Employers & Industry
GSK plans to invest more than $800 million to expand its Upper Merion Township campus in Montgomery County, Pennsylvania, a project the state says will create more than 300 jobs over the next five years.
Gov. Josh Shapiro and Department of Community and Economic Development Secretary Rick Siger announced the investment on Oct. 9. According to the governor’s office, the company will also “retain approximately 4,500 existing full-time jobs” across Pennsylvania. The 300-plus positions are projections spread over five years, not current openings or completed hires, and the retained jobs are existing positions rather than new ones.
The state describes the plan as a biopharmaceutical innovation and manufacturing hub that combines commercial production, research and development, and advanced digital capabilities at one site. The work includes demolishing some existing buildings and building new and upgraded facilities: a commercial-scale biologics plant that can supply both clinical and commercial needs, a co-located R&D pilot plant meant to speed technology transfer and process development, and a centralized quality control lab with a manufacturing science and technology hub. Construction is planned to begin in 2027.
Shapiro said GSK “could have chosen anywhere in the world to expand production.” Regis Simard, president of GSK Global Supply Chain, was quoted describing the investment as additional commercial and R&D manufacturing with advanced digital capabilities at the Upper Merion site.
Why it matters for jobs
The mix of commercial manufacturing, pilot-scale development, quality control and process science under one roof points to demand across production, laboratory and technical support work in the Philadelphia region. The announcement does not list job titles, wages, skill requirements or a hiring schedule, so those details remain unknown.
Pennsylvania’s life-sciences industry is home to approximately 3,900 companies and employs more than 110,000 Pennsylvanians, according to the state. The governor’s office says this is GSK’s second major Pennsylvania expansion under Shapiro, following an $800 million Marietta, Lancaster County, project announced in October 2024. It puts GSK’s combined commitment in the state at nearly $1.7 billion.
Caveats
The state says GSK will be eligible for tax benefits through the Qualified Manufacturing Innovation and Reinvestment Deduction and the Manufacturing Tax Credit programs. The release gives no dollar value for those benefits and no conditions tied to them, and it lists no state grant for the project. Eligibility is not the same as an awarded amount.
GSK previously announced a biologics factory at Upper Merion in September 2025, as part of a larger U.S. investment plan, according to the Pennsylvania Business Report. The governor’s release does not say how the new project relates to that earlier plan, so readers should not combine the figures.
What to watch
Watch for GSK job postings and a hiring timeline, demolition and permitting filings in Upper Merion ahead of the 2027 start, any disclosed incentive values, and whether employment reaches the projected 300-plus over the five-year window.
Sources
- Office of the Governor of Pennsylvania, “Gov. Shapiro Secures Investment from GSK Growing Life Sciences Industry,” October 9, 2026. https://www.pa.gov/governor/newsroom/2026-press-releases/gov–shapiro-secures-investment-from-gsk-growing-life-sciences-i
- Pennsylvania Business Report, GSK biologics flex factory in Upper Merion, September 2025. https://pennbizreport.com/news/31394-new-gsk-biologics-flex-factory-to-be-built-in-upper-merion/
Featured photo: GSK’s building in Brentford, west London, in March 2022. Representative image of the company; not the Upper Merion, Pennsylvania, site. Photo: Jim Linwood, via Wikimedia Commons (CC BY 2.0). Cropped from the original.
